Executive leadership at 60 DEGREES PHARMACEUTICALS.
Board of directors at 60 DEGREES PHARMACEUTICALS.
Research analysts covering 60 DEGREES PHARMACEUTICALS.
Recent press releases and 8-K filings for SXTP.
60 Degrees Pharmaceuticals Completes One-for-Four Reverse Stock Split
SXTP
Delisting/Listing Issues
- 60 Degrees Pharmaceuticals, Inc. (SXTP) has completed a one-for-four (1:4) reverse stock split of its common stock, which became effective on January 20, 2026, at 12:01 AM Eastern Time.
- The primary purpose of this reverse split is to bring the company into compliance with the minimum bid price requirement for maintaining its Nasdaq listing.
- The split reduced the number of issued and outstanding common shares from approximately 5,148,767 to about 1,287,192, with fractional shares rounded up to the next whole number.
Jan 21, 2026, 9:05 PM
60 Degrees Pharmaceuticals Updates on Clinical Timelines and Strategy
SXTP
Earnings
New Projects/Investments
Profit Warning
- 60 Degrees Pharmaceuticals, Inc. made an investor presentation available on January 8, 2026, which included updated information regarding the Company’s clinical development timelines and regulatory strategy.
- The company reported Product Revenues, Net of $438 thousand and a Gross Loss of ($100 thousand) for Q3 2025, noting a net loss due to an anticipated expiring inventory write-off.
- There is substantial doubt as to the company's ability to continue on a going-concern basis.
- The company is pursuing FDA approval for Arakoda for Babesiosis, with the earliest feasible sNDA submission date in Q4 2026, and has outlined key milestones for 2026 related to clinical trials and regulatory strategy.
- The company's market capitalization is $2.1 million.
Jan 8, 2026, 2:00 PM
60 Degrees Pharmaceuticals Provides Update on ARAKODA® Sales Growth and Babesiosis Development
SXTP
Revenue Acceleration/Inflection
New Projects/Investments
Guidance Update
- 60 Degrees Pharmaceuticals (SXTP) reported 140% growth in ARAKODA® net product revenues for fiscal 2024, with current annualized gross sales between $1 million and $2 million and a gross margin percentage stabilized around 50%.
- The company is actively developing ARAKODA® for chronic babesiosis, a market estimated to represent approximately 75% of the product's potential $200 million+ total market by 2035.
- A Breakthrough Therapy Designation request for tafenoquine in relapsing babesiosis was submitted to the FDA in late October 2025, with a decision anticipated in December 2025.
- The earliest feasible NDA submission for babesiosis is projected for the end of 2026, contingent on trial data, while the company's cash runway extends through the end of March 2026.
Oct 22, 2025, 8:15 PM
Sixty Degrees Pharmaceuticals Updates on Arakoda Sales and Chronic Babesiosis Program
SXTP
New Projects/Investments
Revenue Acceleration/Inflection
- Sixty Degrees Pharmaceuticals (SXTP) is advancing its FDA-approved product, Arakoda, which is currently used off-label for chronic Babesiosis and for malaria prevention.
- The company reported annualized gross sales between $1 million and $2 million with a gross margin percentage of approximately 50%.
- SXTP submitted a breakthrough therapy designation request for Arakoda in chronic Babesiosis in October, with feedback expected in December, and anticipates clinical trial data in 2026.
- The estimated market potential for Arakoda in chronic Babesiosis is around $245 million, significantly exceeding the $30 million to $40 million projected for malaria prevention.
- The company's cash runway was projected through March 2026 as of its last financial report, with an update anticipated in mid-November.
Oct 22, 2025, 8:15 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more